Merck KGaA
Merck KGaA is the world's oldest operating chemical and pharmaceutical company, founded in 1668 and headquartered in Darmstadt, Germany, that has strategically reinvented itself as a dual-engine life science and electronic materials powerhouse. In FY2025, the group generated €21.1 billion (~US$23 billion) in global sales, with its Electronics business contributing €3.515 billion (17% of group revenue) through semiconductor solutions and display materials. Having invested over €7 billion in the past five years
Brand
Merck
Founded
1668
Workforce
62,461
Presence
Operations in 65 countries; Electronics business serving all major semiconductor foundries including TSMC, Samsung, Intel, and SK hynix; Asia-Pacific accounts for 72% of Electronics segment revenue; five-year CAPEX exceeding €7 billion in regional manufacturing expansion
Facilities
Over 30 high-purity material production and R&D facilities globally, with major semiconductor solutions manufacturing sites in the USA (Pennsylvania, Texas), Germany (Darmstadt), South Korea (Pyeongtaek), Taiwan (Kaohsiung), and China (Shanghai, Suzhou); specialty gas and precursor synthesis plants in Europe and Asia; display materials production in Korea and Taiwan
Headquarters
Germany
Market
Frankfurt Stock Exchange (MRK)
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is the world's leading provider of scientific services, headquartered in Waltham, Massachusetts, USA. Through its four business segments—Life Sciences, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services—it delivers comprehensive workflow solutions from basic research to clinical application for global pharmaceutical and biotech companies, research institutions, and clinical labs. With revenue of approximately US$50 billion in FY2025, Thermo Fisher has become an infrastructural partner underpinning innovation in the global life sci…
Brand
Thermo Fisher
Founded
1956
Workforce
130K+
Presence
50+ Countries
Facilities
100+ Production Base
Headquarters
United States
Market
NYSE：TMO
Lonza Group is the world's largest contract development and manufacturing organization (CDMO), serving as the foundational manufacturing partner for the global CGT industry.
Lonza Group is the world's largest contract development and manufacturing organization (CDMO), serving as the foundational manufacturing partner for the global CGT industry. In 2025, Lonza generated 6.53 billion Swiss francs ($7.4 billion) in revenue with a 31.6% EBITDA margin. The company scored a landmark achievement by winning the commercial manufacturing contract for CASGEVY at its Geleen, Netherlands facility, the first factory approved across FDA, EMA, and MHRA for CRISPR therapy production.
Strengths: Unmatched global manufacturing infr…
Brand
CDMO
Founded
1897
Workforce
20,000
Presence
Dozens of countries globally
Facilities
30+ major GMP development and manufacturing sites worldwide
Headquarters
Switzerland
Market
SIX: LONN
BASF SE
BASF SE is the world's largest chemical company and the undisputed leader in the plastics and sustainable materials industry, founded in 1865. Headquartered in Ludwigshafen, Germany, BASF's integrated "Verbund" production system — linking 234 production sites across 93 countries — creates an unparalleled ecosystem where byproducts from one process become feedstock for another, achieving industry-leading resource efficiency.
Strengths:
• Unmatched Global Scale: With 2025 revenues of €59.657 billion ($64 billion) …
Brand
BASF
Founded
1865
Workforce
108,251 (Group total); 10,000+ in Agricultural Solutions
Presence
Global operations in 93 countries with 234 production sites including 7 Verbund integrated complexes
Facilities
234 global production sites including 7 core Verbund integrated sites; new BioHub fermentation facility in Ludwigshafen
Headquarters
Germany
Market
Frankfurt Stock Exchange (BAS.DE)
Evonik Industries AG
Evonik is a German specialty chemicals powerhouse headquartered in Essen, Germany. Formed in 2007 with a century-old industrial heritage, the company generated €14.07 billion in 2025 revenue. Its Care division contributed €1.81 billion, specializing in high-purity ceramides, amino acids, and advanced delivery systems. Evonik employs 31,053 people across 100+ production sites in 27 countries. Evonik ranks #3 globally on SpecialChem's cosmetic ingredient supplier popularity index, ren…
Brand
Evonik
Founded
2007
Workforce
31,053
Presence
Global operations in over 100 countries
Facilities
100+ production sites across 27 countries
Headquarters
Germany
Market
Frankfurt Stock Exchange (EVK.DE)
Roquette Frères SA
Roquette is a global leader in plant-based pharmaceutical excipients and specialty carbohydrates, headquartered in Lestrem, France. Founded in 1933, the company generates annual revenue of €4.9 billion and operates 40+ manufacturing sites across the globe, employing 11,000+ people. Roquette's 2025 acquisition of IFF Pharma Solutions transformed it into the world's largest player in oral solid dosage form excipients.
Strengths: Unmatched scale in polyols and starch-der…
Brand
Roquette
Founded
1933
Workforce
11,000+
Presence
Operations in 150+ countries
Facilities
40+ manufacturing sites and 20+ R&D centers globally
Headquarters
France
Market
Private (family-owned)
Croda International Plc
Croda is the world's leading bio-based specialty chemical company, founded in 1925 in Snaith, United Kingdom. Originally a lanolin refiner, Croda has transformed into a premium ingredient powerhouse with 2025 revenue of £1.70 billion and 6.6% constant-currency growth. Its Consumer Care division generated £972 million, with the Fragrance & Flavors sub-segment surging 15%. Croda operates 91 locations in 36 countries, employing 5,954 people. Croda ranks #2 globally on …
Brand
Croda
Founded
1925
Workforce
5,954
Presence
Global, with strong presence in Europe, Americas, and Asia-Pacific
Facilities
91 operating locations across 36 countries
Headquarters
United Kingdom
Market
London Stock Exchange (CRDA.L)
Ashland Inc.
Ashland is a US-based specialty materials company headquartered in Wilmington, Delaware. Founded in 1924 as a refining company, it has transformed into a pure-play specialty additives leader. Following strategic portfolio optimization, Ashland generated $1.82 billion in FY2025 revenue, with its Personal Care division contributing approximately $600 million. The company employs 2,900 people globally. Ashland dominates the cosmetic film-former and cellulose-derived rheology modifier categories with un…
Brand
Ashland
Founded
1924
Workforce
2,900
Presence
Global operations in over 100 countries
Facilities
Multiple specialty polymer production facilities across Americas, Europe, and Asia
Headquarters
United States
Market
New York Stock Exchange (ASH)
Colorcon Inc.
Colorcon is the undisputed global leader in pharmaceutical film coating systems and specialty excipients, headquartered in Harleysville, Pennsylvania, USA. Founded in 1961, the privately-held company generates estimated annual revenue of $750 million and operates 20+ technical service laboratories worldwide, employing 1,300+ people. Its Opadry® brand is the gold standard for oral solid dosage form coating, used in tens of thousands of pharmaceutical products globally.
Strength…
Brand
Colorcon
Founded
1961
Workforce
1,300+
Presence
Direct operations in 25 countries
Facilities
20+ technical service laboratories and dedicated cGMP coating powder manufacturing facilities globally
Headquarters
United States
Market
Private (Berwind subsidiary)
Anhui Shanhe Pharmaceutical Excipients Co., Ltd.
Shanhe Pharmacaps is China's leading pharmaceutical excipient manufacturer and a rising force in global import substitution, headquartered in Huainan, Anhui Province, China. Founded in 2001, the company generated ¥943 million (≈$130 million) in 2025 revenue with net profit surging 47.84% year-over-year, employing 888 people. Listed on the Shenzhen Stock Exchange (SZSE: 300452), Shanhe has emerged as the premier domestic alternative to Western excipient giants.
Strengths: High-…
Brand
Shanhe Pharmacaps
Founded
2001
Workforce
888
Presence
Products exported to dozens of countries worldwide
Facilities
Core production base in Huainan Economic & Technology Development Zone, Anhui; dozens of cGMP-compliant dedicated production lines
Headquarters
China
Market
Listed — SZSE: 300452Frequently Asked Questions
How Do We Generate Our Rankings?
Financial Data Sources
• Annual reports and 10-K filings from the SEC, Frankfurt Stock Exchange, and SIX Swiss Exchange
• Revenue segmentation analysis isolating pharmaceutical raw material and excipient divisions from diversified conglomerates
• Capital expenditure and R&D investment data to gauge commitment to future capacity and innovation
Quality & Regulatory Assessment
• FDA Drug Master File (DMF) registrations and EU EXCIPACT certifications
• cGMP compliance status across global manufacturing facilities
• Track record of regulatory inspections and warning letters from FDA, EMA, and other authorities
Market Position & Brand Strength
• Market share analysis by excipient category (coating systems, binders, disintegrants, lipid nanoparticles)
• Geographic coverage measured by number of countries with direct operations
• Customer concentration and retention metrics where publicly available
Innovation Pipeline
• Investment in next-generation technologies including lipid nanoparticle delivery systems, continuous manufacturing, and green chemistry
• Patent portfolio analysis and new product launch frequency
• Participation in industry consortia and standards-setting bodies
Our composite scoring system (0-100) weights these dimensions equally (25% each) and is recalculated annually to reflect the latest available data. All scores are independently verified against primary sources.
What Defines a Leading Pharmaceutical Raw Materials & Excipients Company?
Technological Mastery and Portfolio Breadth
The most valuable excipient companies are those that can solve complex formulation challenges across the entire drug development lifecycle. Merck KGaA exemplifies this with its Process Solutions division, which provides everything from cell culture media for upstream bioprocessing to chromatography resins for downstream purification — effectively serving as the operating system for biologic drug manufacturing. Similarly, Evonik's EUDRAGIT® and RESOMER® polymer platforms have become the de facto standards for oral modified-release formulations and biodegradable medical devices, creating switching costs so high that generic manufacturers rarely deviate from these established systems.
Regulatory Infrastructure as Competitive Advantage
In an industry where a single excipient change can trigger a multi-year regulatory resubmission process, companies with deep regulatory expertise command extraordinary pricing power. Colorcon has built its entire business model around this dynamic — its Opadry® coating systems are so deeply embedded in regulatory filings that approximately 80% of oral solid dosage products worldwide use Colorcon formulations. BASF leverages its Kollidon® portfolio similarly, with decades of safety data and Drug Master Files that make alternative suppliers prohibitively expensive to qualify.
Global Manufacturing Footprint and Supply Security
Post-pandemic supply chain disruptions have elevated manufacturing geography from an operational detail to a strategic imperative. Roquette's 40+ manufacturing sites and vertically integrated agricultural supply chain provide a level of raw material security that competitors cannot easily replicate. Thermo Fisher Scientific operates over 80 world-class facilities, enabling it to serve as a single-source supplier for pharmaceutical companies seeking to reduce supplier complexity.
Innovation Velocity and Pipeline Depth
The most forward-looking companies are those investing aggressively in next-generation technologies. Croda has positioned itself as the premier supplier of lipid nanoparticles for mRNA delivery systems, capturing disproportionate value in the fastest-growing segment of the pharmaceutical market. Lonza's 19.6% capital expenditure-to-sales ratio and its strategic acquisition of the Vacaville biologics facility demonstrate an appetite for capacity expansion that few competitors can match.
The common thread among top-ranked companies is the ability to transform technical capability into commercial irreplaceability — creating products and services that pharmaceutical manufacturers cannot easily substitute, regardless of price.
How Is the 2025-2026 Pharma Excipients Market Evolving?
Trend 1: The Biologics Revolution Is Reshaping Demand
Monoclonal antibodies, antibody-drug conjugates (ADCs), and cell and gene therapies now represent over 40% of the pharmaceutical industry's R&D pipeline. These modalities require entirely different excipient profiles than traditional small-molecule drugs — demanding high-purity cell culture media, specialized purification resins, and sophisticated delivery vehicles. Thermo Fisher Scientific has capitalized on this shift through its Gibco® brand, which dominates the cell culture media market for biopharmaceutical production. The company's 2025 acquisition of Solventum's filtration business for $3.87 billion directly addresses the downstream purification needs of biologic manufacturers.
Trend 2: Lipid Nanoparticles (LNPs) Emerge as a Strategic Material Class
The success of mRNA COVID-19 vaccines catapulted lipid nanoparticles from a niche research tool to a strategically critical pharmaceutical material. Croda and Evonik have emerged as the primary beneficiaries, with Croda's Life Sciences division achieving a 21.9% EBITDA margin driven largely by high-purity lipid sales. Evonik's $220 million investment in a dedicated lipid innovation center in Lafayette, Indiana, signals confidence that LNP demand will extend far beyond infectious disease vaccines into oncology, rare diseases, and CRISPR-based therapies.
Trend 3: Consolidation Creates Category Kings
The $5+ billion acquisition of IFF Pharma Solutions by Roquette in 2025 created an unprecedented concentration of market power in plant-based oral solid dosage excipients. This deal, combined with Thermo Fisher's string of bolt-on acquisitions, signals that the era of fragmented excipient supply is ending. Regulatory complexity and the cost of maintaining global quality systems favor scale players who can amortize compliance costs across larger revenue bases.
Trend 4: Import Substitution and Supply Chain Regionalization
Geopolitical tensions and pandemic-era supply disruptions have accelerated the trend toward regionalized pharmaceutical supply chains. Shanhe Pharmacaps exemplifies this dynamic from the Chinese perspective, achieving 25%+ export growth by offering FDA-certified, EU EXCIPACT-validated excipients at 30-50% cost savings versus Western alternatives. Meanwhile, BASF's activation of its €10 billion Zhanjiang Verbund site in China and Evonik's expansion in both the US and China reflect a broader industry shift toward "in-region-for-region" manufacturing strategies that prioritize supply security over pure cost optimization.
How Should Buyers Evaluate and Select Pharmaceutical Excipient Suppliers?
1. Regulatory Compliance and Quality Systems
This is the non-negotiable foundation. Verify that potential suppliers hold current certifications appropriate to your target markets: FDA Drug Master Files (DMF) for US-bound products, EU EXCIPACT or CEP certifications for European markets, and relevant pharmacopoeia compliance (USP-NF, Ph. Eur., JP, ChP). Shanhe Pharmacaps demonstrates how emerging suppliers can compete effectively by investing in these credentials — its 15+ FDA DMF filings and successful December 2025 FDA on-site inspection provide the regulatory confidence that Western buyers require. Review a supplier's inspection history, including any FDA Warning Letters or EMA non-compliance reports.
2. Supply Security and Business Continuity
Evaluate the geographic distribution of manufacturing facilities. Single-site suppliers in geopolitically sensitive regions carry inherently higher risk. BASF's six Verbund-integrated sites across three continents and Roquette's 40+ global facilities exemplify the redundancy that pharmaceutical supply chains increasingly demand. Assess whether the supplier maintains safety stock, has documented business continuity plans, and can provide alternative sourcing in the event of a disruption. The 2024 BASF isophytol plant fire — which disrupted vitamin and excipient supply for over 12 months — serves as a sobering case study in concentration risk.
3. Technical Support and Co-Development Capability
The most valuable supplier relationships extend beyond transactional procurement to true technical partnership. Colorcon has built its market dominance on this model — its 20+ global technical service laboratories work alongside customer formulation teams to optimize coating processes, troubleshoot production issues, and accelerate regulatory submissions. Evaluate whether potential suppliers offer application support, custom formulation services, and regulatory filing assistance. The cost of switching excipient suppliers (often requiring new bioequivalence studies) makes the initial selection decision and the quality of ongoing support extraordinarily consequential.
4. Innovation Pipeline Alignment
Assess whether a supplier's R&D investments align with your company's therapeutic focus and future pipeline. Companies developing biologic drugs should prioritize suppliers with deep capabilities in cell culture media (Thermo Fisher Gibco®, Merck KGaA) and purification technologies. Those focused on mRNA or gene therapy platforms need lipid nanoparticle expertise available from Croda and Evonik. Suppliers investing in continuous manufacturing technologies, green chemistry, and novel drug delivery platforms are better positioned to support long-term innovation.
5. Total Cost of Ownership, Not Just Unit Price
While Shanhe Pharmacaps and other emerging-market suppliers offer compelling unit economics (30-50% savings), sophisticated buyers calculate total cost of ownership including qualification costs, regulatory filing amendments, logistics, inventory carrying costs, and the risk-adjusted cost of potential supply disruptions. For high-volume commodity excipients, cost advantages may dominate the decision. For specialized materials critical to a blockbuster drug's performance, reliability and technical support typically justify premium pricing from established leaders like Evonik or BASF.
Which Companies Are Leading in Sustainability and ESG Within the Excipients Industry?
Roquette: Plant-Based Pioneer with Circular Economy Integration
As a company fundamentally built on plant-based chemistry, Roquette has inherent sustainability advantages that synthetic chemical producers cannot easily replicate. The company's raw materials — corn, wheat, peas, and potatoes — are renewable agricultural products, and its manufacturing processes are designed to maximize material utilization with minimal waste. Roquette's 2025 acquisition of IFF Pharma Solutions brings additional expertise in biodegradable and naturally-derived excipient systems. The company has committed to reducing its carbon footprint by 25% by 2030 and sources a growing percentage of its agricultural inputs from regenerative farming programs.
BASF: The Verbund Model as Sustainability Infrastructure
BASF's integrated Verbund production system — where byproducts from one process become raw materials for another — is inherently more resource-efficient than standalone manufacturing. The company's €10 billion investment in its Zhanjiang, China Verbund site incorporates the latest energy-efficient technologies and is designed to ultimately run on 100% renewable electricity. BASF has committed to carbon neutrality by 2050 and has published detailed roadmaps for reducing Scope 1, 2, and 3 emissions across its entire value chain. Its pharmaceutical excipient portfolio increasingly features bio-based and biodegradable alternatives to petroleum-derived materials.
Evonik: Green Chemistry Leadership in High-Value Segments
Evonik has positioned sustainability as a core innovation driver rather than a compliance obligation. The company's EUDRAGIT® and RESOMER® platforms increasingly incorporate bio-based monomers and are designed for end-of-life biodegradability. Evonik has committed to reducing its absolute greenhouse gas emissions by 25% by 2030 (versus 2020 baseline) and has already achieved significant reductions through process optimization and renewable energy procurement. The company's new lipid innovation center in Lafayette, Indiana, is being built to LEED certification standards.
Merck KGaA: Science-Based Targets and Supply Chain Leadership
Merck KGaA has adopted science-based emissions reduction targets aligned with the Paris Agreement's 1.5°C pathway. The company's Life Science division has pioneered the development of animal-origin-free (AOF) cell culture media and recombinant alternatives to animal-derived raw materials, directly addressing ethical concerns in biopharmaceutical manufacturing. Merck's SMASH! packaging reduction program has eliminated thousands of tons of packaging waste from its global supply chain, and the company has committed to making 100% of its packaging recyclable or reusable by 2030.
The common thread among sustainability leaders is the integration of environmental performance into core business strategy rather than treating it as a separate CSR function. Companies that reduce energy consumption, eliminate hazardous solvents, and develop biodegradable materials are simultaneously reducing costs, mitigating regulatory risk, and capturing premium pricing from sustainability-conscious pharmaceutical customers — creating a virtuous cycle that reinforces competitive advantage.